Analysts Set Hims & Hers Health, Inc. (NYSE:HIMS) Target Price at $32.50

Hims & Hers Health, Inc. (NYSE:HIMS) has been given a consensus recommendation of “Hold” by the sixteen brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $32.50.

Several research analysts have weighed in on HIMS shares. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. TD Cowen upped their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research note on Tuesday, August 11th. Barclays lowered their price target on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research report on Friday, August 21st. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Bank of America boosted their price objective on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th.

Insider Buying and Selling

In other news, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $441,850.50. Following the completion of the sale, the chief operating officer directly owned 432,124 shares in the company, valued at approximately $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Oluyemi Okupe sold 4,938 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $29.99, for a total value of $148,090.62. Following the completion of the sale, the chief financial officer owned 264,117 shares of the company’s stock, valued at approximately $7,920,868.83. This trade represents a 1.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 190,227 shares of company stock valued at $6,133,613 in the last quarter. Corporate insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently bought and sold shares of HIMS. Cunning Capital Partners LP acquired a new stake in Hims & Hers Health in the fourth quarter valued at approximately $1,110,000. Norges Bank acquired a new position in shares of Hims & Hers Health during the fourth quarter worth $62,153,000. Virtu Financial LLC bought a new position in shares of Hims & Hers Health in the 4th quarter valued at $1,937,000. Louisiana State Employees Retirement System bought a new position in shares of Hims & Hers Health in the 1st quarter valued at $1,254,000. Finally, Clear Street Group Inc. boosted its holdings in shares of Hims & Hers Health by 23.6% during the 4th quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company’s stock valued at $61,832,000 after acquiring an additional 363,893 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: HIMS finished higher even as the broader market weakened, indicating some buying interest and relative resilience. However, the report did not identify a new earnings, product, or operational development supporting the move. Hims & Hers gains as market dips
• Neutral Sentiment: Hims & Hers is attracting elevated investor attention, which could increase trading activity and volatility. The coverage provides no new outlook, estimates, or company guidance. Hims & Hers investor attention
• Negative Sentiment: Multiple law firms announced or promoted securities class actions against HIMS and certain executives. The lawsuits stem from allegations connected to the FTC’s federal complaint, with investors claiming they were harmed by alleged securities-law violations. These announcements reinforce the company’s legal overhang and could raise potential costs, reputational concerns, and uncertainty around future business practices. Hims & Hers securities class action
• Negative Sentiment: The reported November 2, 2026 lead-plaintiff deadline and repeated investor alerts keep the FTC-related dispute in focus. While these notices do not themselves establish liability or quantify damages, continued litigation publicity may weigh on investor sentiment and contribute to elevated volatility. HIMS investor lawsuit alert

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $28.09 on Wednesday. The company has a market capitalization of $6.55 billion, a price-to-earnings ratio of -44.59 and a beta of 2.42. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $65.30. The stock’s 50 day moving average is $31.43 and its 200-day moving average is $26.99.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.17 earnings per share.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.